Department of Surgery and Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin 03601, Slovakia.
Department of Surgery and Transplantation Centre, University Hospital Martin and Jessenius Medical Faculty of Comenius University, Martin 03601, Slovakia.
Int Immunopharmacol. 2021 Sep;98:107908. doi: 10.1016/j.intimp.2021.107908. Epub 2021 Jun 25.
Infectious complications remain a common cause of mortality after kidney transplantation (KTx). Goal of effective immunosuppressive treatment (IS) must be balanced between decreasing incidence of acute kidney rejection (AKR) and avoiding the incidence of infections, at the same time.
The aim of our analysis was to identify the risk of fixed daily dose (DD) of mycophenolic acid (MPA) and levels of tacrolimus (TAC) in the development of a single, recurrent infection and AKR after KTx.
Our analysis consisted of 100 patients after KTx (66 males, 34 females). MPA DD > 1080 mg was a risk factor (RF) for recurrent infection in general (OR 1.2964;P = 0.0277), for recurrent bacterial infection from 1 to 6 month (OR 1.2674;P = 0.0151), recurrent bacterial infection (OR 1.2574;P = 0.0436), single viral infection (OR 1.2640;P = 0.0398) from 6-12 month after KTx. MPA DD > 1080 mg and levels of TAC above recommended levels were not independent RF for the incidence of the infection.
MPA DD > 1080 mg as a RF for recurrent infection starting in the 1 month after KTx with significant association between the incidence of infections and MPA DD and TAC levels, without increased risk of AKR. In the centers with fixed dosing of IS, this can lead to lowering the risk of infections by decreasing MPA DD 1 month after KTx without increasing risk of infections.
感染并发症仍然是肾移植(KTx)后死亡的常见原因。有效的免疫抑制治疗(IS)的目标必须在降低急性肾排斥(AKR)的发生率和避免感染的发生率之间取得平衡。
我们分析的目的是确定霉酚酸(MPA)固定日剂量(DD)和他克莫司(TAC)水平在 KTx 后单次、复发性感染和 AKR 发展中的风险。
我们的分析包括 100 名 KTx 后的患者(66 名男性,34 名女性)。MPA DD>1080mg 是一般复发性感染的危险因素(OR 1.2964;P=0.0277),1-6 个月复发性细菌感染(OR 1.2674;P=0.0151),复发性细菌感染(OR 1.2574;P=0.0436),6-12 个月后单发性病毒感染(OR 1.2640;P=0.0398)。MPA DD>1080mg 和 TAC 水平高于推荐水平不是感染发生率的独立危险因素。
MPA DD>1080mg 是 KTx 后 1 个月复发性感染的危险因素,感染的发生率与 MPA DD 和 TAC 水平之间存在显著关联,而 AKR 的风险没有增加。在采用固定剂量 IS 的中心,这可以通过在 KTx 后 1 个月降低 MPA DD 来降低感染风险,而不会增加感染风险。